Prediction for oxaliplatin ‐induced liver injury using patient‐derived liver organoids
ConclusionsThese results suggested that L-OHP-induced liver injury may be caused by mitochondrial oxidative damage. Furthermore, patient-derived liver organoids may be used to assess susceptibility to L-OHP-induced liver injury in individual patients. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Kumiko Tatsumi,
Hiroshi Wada,
Shinichiro Hasegawa,
Kei Asukai,
Shigenori Nagata,
Tomoya Ekawa,
Takashi Akazawa,
Yu Mizote,
Shintaro Okumura,
Ryosuke Okamura,
Masayuki Ohue,
Kazutaka Obama,
Hideaki Tahara Tags: RESEARCH ARTICLE Source Type: research
Finding a needle in a haystack: The identification of clinical practice guidelines for psychosocial oncology through an environmental scan of the academic and gray literature
ConclusionSeveral concerns arose from the systematic search. The limited publication of CPGs in peer-reviewed journals may make clinicians and stakeholders more hesitant to implement CPGs due to uncertainties about the methodological rigor of the development process. Further, many existing CPGs are outdated or failed to be updated according to guideline recommendations, meaning that the recommendations may fall short of their purpose to translate up-to-date research findings.Future directionsFuture research should seek to systematically assess the quality of existing psychosocial oncology CPGs and shed light on the current...
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Catherine Bergeron,
Michelle Azzi,
Adina Coroiu,
Carmen G. Loiselle,
Martin Drapeau,
Annett K örner Tags: REVIEW Source Type: research
Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components
ConclusionAmong patients with stage I lung adenocarcinoma with MIP components, those who received ACT showed significant survival benefits compared to those without ACT. Patients with lung adenocarcinoma with MIP components could benefit from ACT when the MIP was ≥1%. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Ying Li,
Junfeng Zhao,
Ying Zhao,
Ruyue Li,
Xue Dong,
Xiujing Yao,
Zhongshuo Xia,
Yali Xu,
Yintao Li Tags: RESEARCH ARTICLE Source Type: research
What do cancer patients experience of the simultaneous care clinic? Results of a cross ‐sectional study on patient care satisfaction
ConclusionOur study shows high levels of satisfactions after SCOC consultation in advanced cancer subjects. Patients' feedback confirmed that SCOC model was effective in helping them during their treatment journey and decision at the end of life. This study encouraged us to enhance our practice of SCOC consultation.Implications for PracticeA joint evaluation of patients living with cancer by oncologist and palliative care team (SCOC-embedded model), has shown to enhance patients' experience/satisfaction with care-such as listening, understanding, receiving information, symptom control, and decision about future, independen...
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Antonella Galiano,
Alessandra Feltrin,
Ardi Pambuku,
Leda Lo Mauro,
Chiara De Toni,
Sabina Murgioni,
Caterina Soldà,
Marco Maruzzo,
Francesca Bergamo,
Antonella Brunello,
Vittorina Zagonel Tags: RESEARCH ARTICLE Source Type: research
Cocaine use and head and neck cancer risk: A pooled analysis in the International Head and Neck Cancer Epidemiology Consortium
ConclusionIn this pooled analysis, we observed a weak positive association between cocaine inhalation and HNC risk. Our findings provide preliminary evidence of the potential carcinogenic effect of cocaine on HNC. Because of study limitations, including limited number of cocaine users, confounding, and heterogeneity across studies, future investigations will require larger studies with more detailed information on cocaine use history. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Mingyan Zhang,
Chu Chen,
Guojun Li,
Alzina Koric,
Yuan ‐Chin Amy Lee,
Hal Morgenstern,
Stephen M. Schwartz,
Erich M. Sturgis,
Paolo Boffetta,
Mia Hashibe,
Zuo‐Feng Zhang Tags: RESEARCH ARTICLE Source Type: research
A multicenter, real ‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
ConclusionsThe modified PD-1 inhibitors showed comparable survival outcomes and manageable safety profiles in NSCLC compared to Pembrolizumab. Moreover, these inhibitors exhibited improved accessibility and economic outcomes compared to Pembrolizumab. While there were similarities in drug-related and immunotherapy-related adverse reactions between the modified PD-1 inhibitors and Pembrolizumab, there were some slight differences. Further prospective and retrospective studies would be necessary to validate these findings beyond the scope of the CTONG1901 study. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Tao Li,
Chao Chen,
Lu Liu,
Jiapei Qin,
Lupeng Qiu,
An Wang,
Weiwei Dong,
Gehan Zhang,
Yao Li,
Lei Zhao,
Fan Zhang,
Yi Hu Tags: RESEARCH ARTICLE Source Type: research
Risk stratification of LA ‐NPC during chemoradiotherapy based on clinical classification and TVRR
ConclusionThe reliance on clinical types and TVRR facilitates risk stratification of NPC during chemoradiotherapy, providing a foundation for physicians to tailor therapeutic strategies. Moreover, the risk cluster delineated for NPC patients during the mid-term of chemoradiotherapy stands as an independent prognostic factor for progression-free survival (PFS), overall survival (OS), distantmetastasis-free survival (DMFS), and local recurrence-free (LRRFS) posttreatment. Additionally, individuals in the high-risk cluster are recommended to undergo adjuvant chemotherapy after CCRT. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Qianlong Tang,
Chaorong Mei,
Bei Huang,
Rui Huang,
Le Kang,
Ailin Chen,
Na lei,
Pengcheng Deng,
Shouyan Ying,
Peng Zhang,
Yuan Qin Tags: RESEARCH ARTICLE Source Type: research
A meta ‐analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy
ConclusionThis study highlighted the comparability of PBT and CIRT in terms of oncological outcomes and adverse events. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Jeong Yun Jang,
Kangpyo Kim,
Miao ‐Fen Chen,
Tetsuo Akimoto,
Michael Lian Chek Wang,
Min‐Ji Kim,
Kyunga Kim,
Tae Hoon Lee,
Gyu Sang Yoo,
Hee Chul Park Tags: RESEARCH ARTICLE Source Type: research
Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital
ConclusionsThis will provide a practical guide for institutions offering naxitamab to their patients, and ensure successful administration of this high acuity treatment in the outpatient setting. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Erin Murphy Trovillion,
Meghan Michael,
Cathryn C. Jordan,
Lauren Brown,
Katlin Phillips,
Javier Oesterheld,
Giselle Saulnier ‐Sholler Tags: METHOD Source Type: research
The association of genomic alterations with PD ‐L1 expression in Chinese patients with EGFR/ALK wild‐type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy
ConclusionsThis study offers insights into genomic features of Chinese EGFR/ALK wild-type lung adenocarcinoma patients based on PD-L1 expression. Notably, Hippo pathway alterations were linked to improved immunotherapy outcomes. These findings suggest connections between the Hippo pathway and PD-L1 expression, warranting further clinical and functional investigations. The research advances our understanding of PD-L1 expression's genomic context and immunotherapy response in EGFR/ALK wild-type lung adenocarcinoma. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Fangfang Liu,
Xuemei Zhang,
Mengyao Lu,
Chun Liu,
Xiaodong Zhang,
Qian Chu,
Yuan Chen,
Peng Zhang Tags: RESEARCH ARTICLE Source Type: research
Issue Information
(Source: Cancer Medicine)
Source: Cancer Medicine - February 23, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Molecular complexity of intraductal carcinoma of the prostate
AbstractIntraductal carcinoma of the prostate (IDC-P) is an aggressive subtype of prostate cancer characterized by the growth of tumor cells within the prostate ducts. It is often found alongside invasive carcinoma and is associated with poor prognosis. Understanding the molecular mechanisms driving IDC-P is crucial for improved diagnosis, prognosis, and treatment strategies. This review summarizes the molecular characteristics of IDC-P and their prognostic indications, comparing them to conventional prostate acinar adenocarcinoma, to gain insights into its unique behavior and identify potential therapeutic targets. (Source: Cancer Medicine)
Source: Cancer Medicine - February 21, 2024 Category: Cancer & Oncology Authors: Sha Zhu,
Nanwei Xu,
Hao Zeng Tags: REVIEW Source Type: research
Schizandrin A induces non ‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation
ConclusionsNetwork pharmacology analyses suggested that ERBB family members may be the targets of SchA. SchA can inhibit NSCLC at least in part by inhibiting EGFR phosphorylation, and activating the EGFR bypass can neutralize the cytotoxicity of SchA. (Source: Cancer Medicine)
Source: Cancer Medicine - February 20, 2024 Category: Cancer & Oncology Authors: Linhai Zhu,
Yanye Wang,
Xuhua Huang,
Xide Liu,
Bo Ye,
Yi He,
Haojie Yu,
Wang Lv,
Luming Wang,
Jian Hu Tags: RESEARCH ARTICLE Source Type: research
Association of blood cell ‐based inflammatory markers with gut microbiota and cancer incidence in the Rotterdam study
To evaluate the association between gut microbiota and the immune response markers NLR, PLR, SII, and WBCs count with the subsequent risk of developing cancer in the Rotterdam study cohort (ERGO). The current study was performed on 8090 participants from the population-based Rotterdam study. A significant association was found between lymphocytes and three gut microbial taxa, namely the family Streptococcaceae, genus Streptococcus, and order Lactobacillales. By analyzing the cancer data, a significant association was observed between higher systemic immune-inflammation index (SII) levels at baseline and a higher count of l...
Source: Cancer Medicine - February 17, 2024 Category: Cancer & Oncology Authors: Shiva Najjary,
Johan M. Kros,
Bruno H. Stricker,
Rikje Ruiter,
Yu Shuai,
Robert Kraaij,
Kristel Van Steen,
Peter van der Spek,
Casper H. J. Van Eijck,
M. Arfan Ikram,
Shahzad Ahmad Tags: RESEARCH ARTICLE Source Type: research
Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA ‐II), serum a‐fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non‐diagnostic serum a‐fetoprotein levels
ConclusionsEach biomarker separately showed acceptable accuracy for detecting HCC in cirrhotic patients and excellent for those in BCLC-C stage. The combination of the biomarkers presented excellent results in BCLC-B/C patients. The diagnostic accuracy of PIVKA-II and the combination of the two biomarkers in patients expressing low/non-diagnostic AFP levels was good in BCLC-B and excellent in BCLC-C patients. (Source: Cancer Medicine)
Source: Cancer Medicine - February 16, 2024 Category: Cancer & Oncology Authors: Antonia Syriha,
Spyridon Pantzios,
Dionysia Mandilara,
Petros Galanis,
Ioanna Stathopoulou,
Georgia Barla,
Ioannis Elefsiniotis Tags: RESEARCH ARTICLE Source Type: research
